Only a slight fraction of the Black and Latino population who would likely stand to benefit from Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) are actually receiving the HIV prevention method, according to a new analysis from the Centers for Disease Control and Prevention (CDC). Of the estimated 1.1 million U.S. residents who are likely good PrEP candidates according to CDC guidelines, 71 percent are men who have sex with men, 23 percent are high-risk heterosexuals and 6 percent are people who inject drugs. All told, an estimated 44 percent of those indicated for PrEP are Black, 25 percent are Latino and 27 percent are white. The CDC estimates that 14 percent of white, 3 percent of Latino, 1 percent of Black and 8 percent of all individuals indicated for PrEP received Truvada for prevention between September 2015 and August 2016.
Concerns: PrEP Disparities
The CDC reports that PrEP use is low among Blacks and Latinos.